Lipella Pharmaceuticals Inc. (LIPO) Stock Analysis & Investment Frameworks
Lipella Pharmaceuticals Inc. (LIPO) stock analysis on Invetso. Review Lipella Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Lipella Pharmaceuticals Inc. Company Overview
- Exchange: Other OTC
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Lipella Pharmaceuticals Inc. Key Financial Metrics
- Market Cap: $2310.00
- Revenue: $536357.00
- ROE: -122.08%
- ROIC: -150.19%
- Dividend Yield: N/A
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies. The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications. Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis. Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.